Last year, GlaxoSmithKline ( NYSE: GSK ) quietly backpedaled away from a marketing snafu that’s now come to light. The company had sponsored a supplement to the journal Urology on prostate cancer–one that conveniently touted its prostate drug Avodart–but didn’t fully disclose its financial support for the publication. Nor…
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has reservations on approval by the U.S. Food and Drug Administration (FDA) of another version of enoxaparin sodium.
Original Source of Sanofi-aventis expresses concern over the approval of another version of enoxaparin sodium
Bloomberg is reporting that Genzyme has rejected Sanofi-Aventis’ offer for the company. Citing people familiar with the matter, the Wall Street Journal reported last Friday that the
FDA advisory panel members overwhelmingly rejected a plan to reduce the misuse and abuse of long-acting painkillers like OxyContin, saying they did not think it was strong enough to control the use of such prescription narcotics. Report
Original Source of FDA panel: Painkiller plan not strong enough
In the ongoing fight about sales rep overtime pay, chalk up a win for management. As BNet Pharma reports, reps at King Pharmaceuticals’ ( NYSE: KG ) Alpharma unit lost their bid to break out of the overtime exemption. The judge’s ruling brings the number of overtime cases decided…
The FDA is looking to higher-ups for help sorting out a potential conflict of interest on the recent Avandia advisory panel. After news emerged last week that one panelist, endocrinologist David Capuzzi, had been paid to speak on behalf of a GlaxoSmithKline ( NYSE: GSK ) product, agency officials…
Neuromuscular diseases (NMDs) are chronic and so far incurable conditions that gradually affect patients’ muscles, leading to potentially severe disabilities. Biomedical researchers are busy looking for the diseases’ Achilles’ heel.
Original Source of Tracking down neuromuscular diseases
Sanofi-Aventis ( NYSE: SNY )
Sanofi-Aventis sales reps have won a settlement in their gender bias case against the company, but it’s a small fraction of the big Novartis deal announced last week. One-tenth of the size, to be exact. Lawyers for the 5,200 current and former Sanofi reps asked a judge to approve…